Avere Therapeutics announced a $500 million private placement, adding to a previously announced $320 million concurrent investment for $820 million in committed financing [1]. The money is earmarked for AVR-001, a once-weekly oral IL-23 receptor antagonist the company is developing initially for psoriasis, with potential expansion into ulcerative colitis, Crohn's disease, and psoriatic arthritis [1].
The raise is tied to a planned reverse merger. Avere will combine with NextCure, a Nasdaq-listed company trading under NXTC, in an all-stock transaction expected to close in the second half of 2026 [1]. The combined company would keep the Avere Therapeutics name and trade on Nasdaq under the ticker AVRX [1]. The investor syndicate includes Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, and RTW Investments, among others [1].
Avere said the $500 million placement together with the prior $320 million is expected to fully fund its operating plan into 2029 [1]. That runway is the point of the financing: the capital is being lined up ahead of clinical readouts, not after them, and a reverse merger delivers a public listing without the scrutiny of a conventional initial public offering.
The arithmetic is straightforward. The new placement of $500 million plus the earlier $320 million totals $820 million [1]. What that $820 million buys is time, not proof. A program funded into 2029 still has to show AVR-001 works before the money returns anything to the investors staking it.
